

1 **Title**

2 Dose-response modelling of endemic coronavirus and SARS-CoV-2: human challenge trials
3 reveal the individual variation in susceptibility

4
5 **Authors**

6 Fuminari Miura^{1,2}, Don Klinkenberg¹, Jacco Wallinga^{1,3}

7
8 **Affiliations**

9 ¹ Centre for Infectious Disease Control, National Institute for Public Health and the
10 Environment, Bilthoven, The Netherlands

11 ² Center for Marine Environmental Studies, Ehime University, Matsuyama, Japan

12 ³ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The
13 Netherlands

14
15 **Corresponding author**

16 F. Miura (fuminari.miura@rivm.nl)

17
18 **Keywords**

19 SARS-CoV-2, endemic coronavirus, human challenge trial, dose-response model

20
21 **Running title**

22 Dose-response model for coronaviruses

23
24 **One sentence summary**

25 We rephrase dose-response models in terms of heterogeneity in susceptibility in order to
26 present the possible range of infection risks for endemic coronaviruses and SARS-CoV-2

27
28 **Article type**

29 Brief reports

30
31 **Word count (main text)**

32 1500 words

33
34 **Abstract**

35 We propose a mathematical framework to analyze and interpret the outcomes of human
36 challenge trials. We present plausible infection risks with HCoV-229E and SARS-CoV-2
37 over a wide range of infectious dose, and suggest ways to improve the design of future trials
38 and to translate its outcomes to the general population.

39

40 Main text

41

42 Background

43 Quantifying the infectivity of pathogens is a crucial step towards the understanding of
44 infection risks. In human challenge trials the infection risk is observed as the proportion of
45 exposed participants that become infected. Dose-response models describe how this
46 proportion infected changes with an increase in the infectious dose used to expose the
47 participant [1,2]. Such dose-response models can be used to improve trial designs [3], to
48 describe infectivity and immunogenicity in human hosts [4], and to simulate the infection
49 risks via various transmission routes [5].

50 Dose-response models can account for variation in host susceptibility, and most often such
51 variation has been modelled by a beta distribution [6,7]. However, when a proportion of
52 individuals is completely immune, the variation is better captured by other distributions (e.g.,
53 [8]).

54 Here, we start by reformulating dose-response models with a flexible description of the
55 variation in host susceptibility that allows for an intuitive biological interpretation. We show
56 how variation in susceptibility determines the dose-response relationship for the endemic
57 human coronavirus HCoV-229E and we compute the plausible range of SARS-CoV-2 dose-
58 response curves based on available outcomes of a challenge study.

59 Our approach suggests how the design of human challenge trials can be improved to better
60 capture the variation in susceptibility, and suggests how to translate the outcomes of human
61 challenge studies into infection risks for the general population.

62

63 Methods

64 Human challenge studies

65 We conducted a literature search to collect available data from human challenge studies
66 with endemic coronaviruses and SARS-CoV-2. The collected data consists of 5 studies with
67 endemic coronaviruses HCoV 229E and one study with SARS-CoV-2. In all cases the study
68 population consisted of healthy adult volunteers, and the participants were intranasally
69 inoculated with certain doses in each trial. The challenge studies reported the challenge dose,
70 the number of challenged individuals, and the number of infected individuals as summarized
71 in **Supplementary Material, Table S1** and **Table S2**.

72

73 Dose-response models to analyze human challenge studies

74 The reported infectious doses d are expectations of a Poisson distribution of the actual
75 infectious dose, with mean d . If each host is equally susceptible, the probability of infection
76 $P(d)$ given a challenge dose d is $P(d) = 1 - \exp(-d)$. This assumes that each infectious
77 particle can independently establish an infection [2,9].

78 We capture the variation in susceptibility among study participants by assigning each a
79 level of susceptibility s , according to a distribution $f(s)$ with mean 1. A participant with a
80 level of susceptibility s has s times higher probability of infection compared to an average
81 individual, per infectious particle. The probability of infection upon challenge with a dose d
82 is $P(d) = 1 - \int_0^\infty \exp(-sd)f(s)ds$. By fitting this model for the probability of infection to
83 the observed proportion of infections in human challenge studies we can infer the shape of the
84 distribution $f(s)$ using the method of maximum likelihood, see **Supplementary Material** for

85 details. We use four different models for the distribution: a Dirac delta distribution to reflect
86 a situation where all individuals have the same level of susceptibility; a gamma distribution
87 to reflect a situation where the level of susceptibility varies continuously; a bimodal
88 distribution with one fraction of the population almost immune, and the remaining fraction
89 with a single level of susceptibility; and a bimodal distribution with one fraction of the
90 population almost immune, and the remaining fraction with a gamma distribution for the level
91 of susceptibility to vary continuously. Detailed model descriptions and estimated parameters
92 are provided in **Table S3**.

94 **Results**

95 Susceptibility distributions determine the shape of dose-response curves

96 We described the proportion of infections among individuals exposed to different doses of
97 the endemic coronavirus HCoV-229E by fitting dose-response models. Since the collected
98 trial data include participants who might have been exposed to viruses, we included bimodal
99 distributions of susceptibility.

100 The results reveal a strong statistical support for a distribution reflecting a situation where
101 a fraction of the population is almost immune whereas the remaining fraction of the population
102 has a single level of susceptibility. There is no statistical support for a homogeneous level of
103 susceptibility or continuous variation in susceptibility for all individuals (**Table S4**).

104
105 Plausible SARS-CoV-2 dose-response curves

106 In the available human challenge study with SARS-CoV-2 all participants were healthy
107 young adults with no evidence of previous SARS-CoV-2 infection or vaccination, and they
108 were all exposed to the same single dose [10]. Here we show how the variation in
109 susceptibility would affect the infection risk at different doses. Since participants had not had
110 any prior exposure to this virus, we assumed a continuous variation in susceptibility only. We
111 fitted the model with several gamma distributions for the level of susceptibility s to the
112 observed SARS-CoV-2 challenge data, where we increased the coefficient of variation (CV)
113 over orders of magnitude from small (10^{-6}) to large (10^2). The corresponding curves reveal
114 that the infection risk increases more gradually with increasing CV in susceptibility (**Figure**
115 **1A**).

116 We accounted for the statistical uncertainty in the fraction of the participants that were
117 infected by taking 1000 bootstrap samples and fitting dose-response curves to each
118 bootstrapped dataset, reflecting a situation where the susceptibility level is completely
119 homogeneous ($CV = 0$), and where the level is similar to that of the endemic coronavirus
120 infection ($CV = 1$)(**Figure 1B** and **1C**).

121 We compared the bootstrapped SARS-CoV-2 dose-response curves with the dose-response
122 curve from a SARS-CoV-1 mouse model obtained by Watanabe et al. [11], which has been
123 widely used in risk assessments of SARS-CoV-2 (dotted lines in **Figure 1**). This reveals that
124 using the current reference model based on mouse data with SARS-CoV-1 could lead to
125 serious underestimation of the infection risk for SARS-CoV-2, irrespective of the shape of the
126 distribution of susceptibility level. We also compared the SARS-CoV-2 dose-response curves
127 with the observed outcomes from the challenge studies with endemic coronavirus (**Figure**
128 **1D**). This suggests that the estimated range of infection risks of endemic coronavirus is
129 consistent with the observed infection risk in the SARS-CoV-2 trial [12].

130

131 Discussion

132 In this study, we revealed the plausible range of infection risk over multiple orders of
133 magnitude of the infectious dose for the endemic coronavirus HCoV 229E and SARS-CoV-
134 2, based on human challenge trials. We presented how these dose-response relationships are
135 shaped by the underlying distribution of susceptibility to infection.

136 The range of SARS-CoV-2 dose-response curves arises from the unknown distribution of
137 background susceptibility in the population and the statistical uncertainty due to the limited
138 number of participants that have participated in the human challenge study. Our results
139 caution against assuming equal susceptibility in the population in risk assessments [5,11], as
140 this assumption results in a lower bound for infection risks at lower doses.

141 Our results provide implications for further research. We address three of them here.

142 Firstly, our approach suggests a possible improvement in the design of human challenge
143 trials. Conventional trials tend to use a single dose such as the median human infectious
144 dose (HID_{50}) [13]. Using two (or more) challenge doses would be highly informative for
145 extrapolating the findings over a wider range of doses. If multiple challenge doses would not
146 be feasible, we advise to consider using a different challenge dose than the doses used in
147 previous studies. The outcomes of the different studies can be combined in a meta-analysis
148 that takes advantage of those different doses to infer how infection risk changes with dose.
149 This would elucidate the unknown variation in level of susceptibility among individuals.

150 Secondly, the dose-response models proposed here, as many other dose-response models,
151 have underlying assumptions that the infectious particles are homogeneously mixed in the
152 inoculates and act independently in causing an infection [2,9]. These assumptions suffice for
153 describing the outcome of human challenge studies, even though it might not hold, for
154 example, when virus particles aggregate. The dose-response model can be extended to allow
155 for variation in the per-particle probability, using methods explored previously [2,14], which
156 would allow for a built-in check of violating this assumption.

157 Thirdly, our approach offers guidance for the translation of the observed risk of infection
158 in human challenge studies to the general population. Currently this translation is difficult as
159 the study population of challenge studies, due to safety and ethical reasons, consists of
160 healthy adult volunteers [15]. Such a study population is not representative of a general
161 population which includes children and elderly. Besides, the general population now
162 includes persons who have been exposed to SARS-CoV-2. The strict selection of healthy
163 adult study participants with no evidence of previous exposure inevitably reduces the
164 variation in susceptibility relative to the general population. The proposed dose-response
165 models with flexible distribution of susceptibility allows for exploring the impact of an
166 expected increase in variability of the level of susceptibility in the general population and a
167 flattening of the dose-response curve.

168 In conclusion, our study reveals plausible dose-response relationships for SARS-CoV-2,
169 based on information from human challenge trials, that are consistent with dose-response
170 curves obtained for human endemic coronaviruses. Human challenge trials would be more
171 informative if they use different doses. When translating the observed infection risks in the
172 specific study population to the general population, the expected higher variability of
173 susceptibility in the general population should be taken into account.

174

175 **References**


- 176 1. Furumoto WA, Mickey R. A mathematical model for the infectivity-dilution curve of tobacco
177 mosaic virus: theoretical considerations. *Virology* **1967**; 32:216–223.
- 178 2. Haas CN, Rose JB, Gerba CP. *Quantitative Microbial Risk Assessment*. John Wiley & Sons,
179 2014.
- 180 3. Atmar RL, Opekun AR, Gilger MA, et al. Determination of the 50% human infectious dose for
181 Norwalk virus. *J Infect Dis* **2014**; 209:1016–1022.
- 182 4. Clements ML, Snyder MH, Sears SD, Maassab HF, Murphy BR. Evaluation of the infectivity,
183 immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant
184 virus vaccine in adult volunteers. *J Infect Dis* **1990**; 161:869–877.
- 185 5. Zhang X, Wang J. Dose-response Relation Deduced for Coronaviruses From Coronavirus
186 Disease 2019, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome:
187 Meta-analysis Results and its Application for Infection Risk Assessment of Aerosol
188 Transmission. *Clin Infect Dis* **2021**; 73:e241–e245.
- 189 6. Teunis PF, Havelaar AH. The Beta Poisson dose-response model is not a single-hit model.
190 *Risk Anal* **2000**; 20:513–520.
- 191 7. Gomes MGM, Lipsitch M, Wargo AR, et al. A missing dimension in measures of vaccination
192 impacts. *PLoS Pathog* **2014**; 10:e1003849.
- 193 8. Halloran ME, Longini IM Jr, Struchiner CJ. Estimability and interpretation of vaccine efficacy
194 using frailty mixing models. *Am J Epidemiol* **1996**; 144:83–97.
- 195 9. Nilsen V, Wyller J. QMRA for Drinking Water: 1. Revisiting the Mathematical Structure of
196 Single-Hit Dose-Response Models. *Risk Anal* **2016**; 36:145–162.
- 197 10. Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-
198 CoV-2 human challenge in young adults. *Nat Med* **2022**; :1–11.
- 199 11. Watanabe T, Bartrand TA, Weir MH. Development of a dose - response model for SARS
200 coronavirus. *Risk Anal* **2010**; Available at:
201 <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1539-6924.2010.01427.x>.
- 202 12. Killingley B, Mann A, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-
203 CoV-2 human challenge. *Research Square*. 2022; Available at:
204 <https://www.researchsquare.com/article/rs-1121993/v1>.
- 205 13. Levine MM, Abdullah S, Arabi YM, et al. Viewpoint of a WHO Advisory Group Tasked to
206 Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019
207 (COVID-19) in Healthy Volunteers. *Clin Infect Dis* **2021**; 72:2035–2041.
- 208 14. Teunis PFM, Brienen N, Kretzschmar MEE. High infectivity and pathogenicity of influenza A
209 virus via aerosol and droplet transmission. *Epidemics* **2010**; 2:215–222.
- 210 15. Jamrozik E, Littler K, Bull S, et al. Key criteria for the ethical acceptability of COVID-19
211 human challenge studies: Report of a WHO Working Group. *Vaccine* **2021**; 39:633–640.

213 **Acknowledgements**

214 **Funding:** FM acknowledge funding support from JSPS KAKENHI (Grant number
215 20J00793). This project has received funding from the European Union's Horizon 2020 research
216 and innovation programme - project EpiPose (JW and DK, Grant agreement number 101003688).
217 This work reflects only the authors' view. The European Commission is not responsible for any use
218 that may be made of the information it contains. **Competing interests:** The authors declare no
219 competing interests. **Data and materials availability:** all codes and analyzed data are available at
220 the author's GitHub link (https://github.com/fmiura/CoronaDR_2022).

221

222 Figures and Tables



223
224 **Figure 1.** Dose-response curves of SARS-CoV-2 (panel **A**, **B**, and **C**) and comparison with an
225 estimated dose-response curve of endemic coronaviruses (panel **D**) based on observed human
226 challenge data. In panel **A-C**, light red dots stand for observations from human challenge data of
227 SARS-CoV-2 (**Table S2**), and whiskers show Jeffrey's binomial confidence intervals (95%). Panel
228 **A** illustrates that the steepness of fitted curves (blue lines) decreases over the increase in the
229 coefficient of variation (CV) in susceptibility from 10^{-6} to 10^2 . Panel **B** and **C** show curves fitted to
230 1000 bootstrapped samples from observed data where the CV is set as 0 and 1 respectively. These
231 values are selected to consider two scenarios where the susceptibility level is completely
232 homogeneous and where the level is comparable to that of endemic coronavirus infection. Dotted
233 grey lines show reference dose-response curves of SARS-CoV-1 animal model [11]. In panel **D**, plots
234 and whiskers are observed challenge data of endemic coronaviruses (**Table S1**), and dark and light
235 blue lines indicate fitted SARS-CoV-2 models where the CV is fixed as 0 and 1 respectively.

Supplementary Materials for

Dose-response modelling of endemic coronavirus and SARS-CoV-2: an implication for future human challenge trials

Fuminari Miura, Don Klinkenberg, Jacco Wallinga.

Correspondence to: fuminari.miura@rivm.nl

Table of contents:

Materials and Methods

- Human challenge data
- Rephrased dose-response model
- Model fitting
- Referred animal dose-response model

References

Supplementary figures and tables

- Figure S1.** Estimated dose-response models of endemic coronavirus.
- Figure S2.** Simulated trajectories of SARS-CoV-2 dose response curves.
- Table S1.** Human challenge data with endemic coronavirus.
- Table S2.** Human challenge data with SARS-CoV-2
- Table S3.** Model description and estimated parameters.
- Table S4.** Model comparison of dose-response models employing different distributions.

Materials and Methods

Human challenge data

The challenge data of endemic coronaviruses and SARS-CoV-2 were collected from published articles. We conducted literature search using PubMed and Google Scholar, and 13 human challenge studies were found in total. For further analysis, 7 studies [1–7] were excluded because the information on inoculated doses was unavailable. Thus, 5 studies of endemic coronaviruses [8–12] and 1 study of SARS-CoV-2 [13] were used in the dose-response analysis. The data consisted of the number of exposed doses, total participants, and infected individuals in each trial. The summary of analyzed data with details (i.e., inoculation methods and references) is shown in **Table S1**.

To synthesize the obtained data, we set two assumptions. First, the infection status was comparable across those studies. Several studies defined the infection status by antibody level, while others defined it by the presence of viruses. Second, there was negligible effect of aggregation of viruses. Since the detailed information of inoculated samples was not available, the unit of dose is defined as the reported unit (i.e., TCID₅₀, Median tissue culture infectious dose). If there is data that quantify the level of aggregation, further extension of the dose-response analysis is also possible (see [14,15]).

Rephrased dose-response model

Here we denote the probability of infection in controlled infection experiments as $P_{inf}(d)$, a function of dose d . In a host, it is reasonable to assume that all the particles are independently infectious and effective to establish an infection (i.e., single-hit theory [15,16]). The simplest dose-response relationship is formulated by incorporating Poisson uncertainty in a microbial inoculum:

$$P_{inf}(d; r) = 1 - \exp(-rd) \quad Eq. 1$$

where r is the probability of establishing infection by a single-hit.

While previous studies formulated the variation in r (often with a beta distribution [15,17–19]), here we focus on the variation in a host. Suppose that the susceptibility to infection among individuals differs and is distributed as $f(s)$ with a level of susceptibility s . The interpretation of variable s is that an individual with the level of susceptibility $s = s'$ has s' times higher probability of infection compared to an individual with $s = 1$. By expanding Eq.1 and integrating the variation in susceptibility, the marginal probability of infection is written as

$$P_{inf}(d; r, \theta) = 1 - \int_0^{\infty} \exp(-rds) f(s; \theta) ds \quad Eq. 2$$

where θ is a parameter vector of $f(s)$. If a single-hit always results in infection, that is, $r = 1$, Eq.2 can be further simplified

$$P_{inf}(d; \theta) = 1 - \int_0^{\infty} \exp(-ds) f(s; \theta) ds = 1 - \mathcal{L}_s(d) \quad Eq. 3$$

where \mathcal{L}_s refers to the Laplace transform of $f(s)$.

As an illustrative example, we introduce the dose-response model where the level of susceptibility is distributed as a Gamma distribution, $s \sim \text{Gamma}(\alpha, \beta)$. By solving Eq.3, the dose-response model is derived as

$$P_{inf}(d; \alpha, \beta) = 1 - \left(1 + \frac{d}{\beta}\right)^{-\alpha} \quad Eq. 4$$

and this formula is the same as the so-called Beta-Poisson model [15,19]. Note that we can derive Eq.4 without violating the single-hit principle, and the equation can be interpreted as the relationship between dose-dependent infection probability and the susceptibility distribution within a host.

Model fitting

Since the results of controlled infections are obtained as either infected or not in challenge experiments, such observation process leads to a binomial likelihood

$$L(\boldsymbol{\theta}) = \prod_i (1 - P_{inf}(d_i))^{(n_i - m_i)} P_{inf}(d_i)^{m_i}$$

and thus the log-likelihood is

$$\ell(\boldsymbol{\theta}) = \sum_i [(n_i - m_i) \ln(1 - P_{inf}(d_i)) + m_i \ln(P_{inf}(d_i))]$$

where for each trial i we have a dose d_i and a group of n_i volunteers of which m_i are infected. To estimate the set of parameters $\boldsymbol{\theta}$, maximum likelihood estimation (MLE) was performed. For this computation we used the `optim()` function in the R statistical programming environment version 3.5.1., and 95 % confidence intervals were computed from 1000 bootstrapped samples.

Referred animal dose-response model

Current risk assessments of SARS-CoV-2 infection risk among humans often refer to the animal dose-response model obtained by Watanabe et al. [20]. Their study used a Delta model (i.e., the first model in **Table S3**) and fitted it to available SARS-CoV-1 data based on mouse experiments. As a result, the estimated parameter was $a = \frac{1}{410}$ in **Table S3** notation. For details, see the original article [20]. For comparison of dose-response curves, we converted the unit of inoculated doses using the ratio of PFU to TCID₅₀ that is previously established as 0.7 [21].

References

1. Kraaijeveld CA, Reed SE, Macnaughton MR. Enzyme-linked immunosorbent assay for detection of antibody in volunteers experimentally infected with human coronavirus strain 229 E. *J Clin Microbiol.* **1980**; 12(4):493–497.
2. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. *Antimicrob Agents Chemother.* **1983**; 24(5):713–715.
3. Bradburne AF, Somerset BA. Coronative antibody titres in sera of healthy adults and experimentally infected volunteers. *J Hyg.* **1972**; 70(2):235–244.
4. Macnaughton MR, Hasony HJ, Madge MH, Reed SE. Antibody to virus components in volunteers experimentally infected with human coronavirus 229E group viruses. *Infect Immun.* **1981**; 31(3):845–849.
5. Bradburne AF. Antigenic relationships amongst coronaviruses. *Arch Gesamte Virusforsch.* **1970**; 31(3):352–364.
6. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. *N Engl J Med.* **1991**; 325(9):606–612.
7. Callow KA. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. *J Hyg.* **1985**; 95(1):173–189.
8. Bradburne AF, Bynoe ML, Tyrrell DA. Effects of a “new” human respiratory virus in volunteers. *Br Med J.* [ncbi.nlm.nih.gov](https://doi.org/10.1136/bmj.3.5568.767); **1967**; 3(5568):767–769.
9. Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains. *J Med Virol.* **1984**; 13(2):179–192.
10. Bende M, Barrow I, Heptonstall J, et al. Changes in human nasal mucosa during experimental coronavirus common colds. *Acta Otolaryngol.* **1989**; 107(3–4):262–269.
11. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect.* **1990**; 105(2):435–446.
12. Tyrrell DA, Cohen S, Schlarb JE. Signs and symptoms in common colds. *Epidemiol Infect.* **1993**; 111(1):143–156.
13. Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. *Nat Med.* Nature Publishing Group; **2022**; :1–11.
14. Teunis PFM, Brienen N, Kretzschmar MEE. High infectivity and pathogenicity of influenza A virus via aerosol and droplet transmission. *Epidemics.* **2010**; 2(4):215–222.
15. Haas CN, Rose JB, Gerba CP. *Quantitative Microbial Risk Assessment.* John Wiley & Sons; 2014.
16. Furumoto WA, Mickey R. A mathematical model for the infectivity-dilution curve of tobacco mosaic virus: theoretical considerations. *Virology.* **1967**; 32(2):216–223.
17. Nilsen V, Wyller J. QMRA for Drinking Water: 1. Revisiting the Mathematical Structure of Single-Hit Dose-Response Models. *Risk Anal.* **2016**; 36(1):145–162.
18. Gomes MGM, Lipsitch M, Wargo AR, et al. A missing dimension in measures of vaccination impacts. *PLoS Pathog.* [journals.plos.org](https://doi.org/10.1371/journal.ppat.1003849); **2014**; 10(3):e1003849.
19. Teunis PF, Havelaar AH. The Beta Poisson dose-response model is not a single-hit model. *Risk Anal.* **2000**; 20(4):513–520.
20. Watanabe T, Bartrand TA, Weir MH. Development of a dose - response model for SARS coronavirus. *Risk Anal* [Internet]. Wiley Online Library; **2010**; . Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1539-6924.2010.01427.x>
21. Covés-Datson EM, King SR, Legendre M, et al. A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. *Proc Natl Acad Sci U S A.* National Acad Sciences; **2020**; 117(4):2122–2132.
22. Burnham KP, Anderson DR. *Multimodel Inference: Understanding AIC and BIC in Model Selection.* Sociol Methods Res. SAGE Publications Inc; **2004**; 33(2):261–304.

Supplementary figures and tables




Figure S1. Estimated dose-response models of endemic coronavirus based on observed human challenge data. Grey bubbles indicate the observed data, and the size of bubbles indicates the number of participants in each trial. To describe different heterogeneity in susceptibility, dose-response models with Delta (panel **A**), Gamma (panel **B**), Two-level (panel **C**), and Gamma with point-mass distributions (panel **D**) were fitted to the data.




Figure S2. Simulated SARS-CoV-2 dose response curves based on observed human challenge data. Red plot and whiskers indicate the observed data and its 95% binomial confidence intervals. Each curve is obtained by bootstrapping with a gamma model. From panel **A** to **F**, the coefficient of variation is decreased from 10^2 to 10^{-3} .

Table S1. Human challenge data with endemic coronavirus.

Dose	Total	Infected	Unit	Pathogen	Age	Inoculation	Reference
100	24	21	TCID50*	HCoV-229E	21-53	Nasal drop	Bende 1989 (Table 1)
31.6	6	4	TCID50	HCoV-229E	18-50	Nasal drop	Bradburne 1967 (Fig 1)
5.0	6	1	TCID50	HCoV-229E	18-50	Nasal drop	Bradburne 1967 (Fig 1)
4.0	5	2	TCID50	HCoV-229E	18-50	Nasal drop	Bradburne 1967 (Fig 1)
15.8	9	6	TCID50	HCoV-229E	18-50	Nasal drop	Bradburne 1967 (Fig 1)
100	15	10	TCID50	HCoV-229E	Unknown	Nasal drop	Callow 1990 (Main text)
17.8	22	7	TCID50	HCoV-229E	18-50	Nasal drop	Reed 1984 (Table V)
31.6	24	12	TCID50	HCoV-229E	18-50	Nasal drop	Reed 1984 (Table V)
15848.9	12	7	TCID50	HCoV-229E	18-50	Nasal drop	Reed 1984 (Table V)
100	55	50	TCID50	HCoV-229E	18-53	Nasal drop	Tyrell 1993 (Table 2)

†TCID50: Median tissue culture infectious dose.

Table S2. Human challenge data with SARS-CoV-2.

Dose	Total	Infected	Unit	Pathogen	Age	Inoculation	Reference
10	34	18	TCID50*	SARS-CoV-2†	18-29	Nasal drop	Killingley 2022

*TCID50: Median tissue culture infectious dose.

†Pre-alpha wild-type virus (Genbank accession number OM294022).

Table S3. Description of dose-response models with different distributions for describing the heterogeneity in susceptibility against endemic coronavirus and its estimated parameters.

Susceptibility distribution	Dose-response model	Estimated parameters	Description
Delta	$P_{inf}(d) = 1 - \exp(-ad)$	$a = 1.3 \times 10^{-3}$ [$6.6 \times 10^{-4}, 2.3 \times 10^{-3}$]	All individuals have the same level of susceptibility, and the variance is zero.
Gamma	$P_{inf}(d) = 1 - (1 + \theta d)^{-k}$	$\theta = 1.2$ [$1.4 \times 10^{-1}, 3.9 \times 10^2$] $k = 2.7 \times 10^{-1}$ [$1.1 \times 10^{-1}, 5.3 \times 10^{-1}$]	The level of susceptibility for all individuals follows a gamma distribution.
Two-level	$P_{inf}(d) = 1 - [p_1 \exp(-a_1 d) + (1 - p_1) \exp(-a_2 d)]$	$a_1 = 4.2 \times 10^{-9}$ [$5.8 \times 10^{-13}, 2.5 \times 10^{-5}$] $a_2 = 4.2 \times 10^{-2}$ [$1.9 \times 10^{-2}, 6.9 \times 10^{-2}$] $p_1 = 1.7 \times 10^{-1}$ [$1.4 \times 10^{-3}, 2.4 \times 10^{-1}$]	A population has two levels of susceptibility; a proportion (p_1) has a mass at level of susceptibility a_1 and the other has another mass at level of susceptibility a_2 .
Gamma with point mass	$P_{inf}(d) = 1 - [p_1 \exp(-a_1 d) + (1 - p_1)(1 + \theta d)^{-k}]$	$a_1 = 7.5 \times 10^{-17}$ [$9.7 \times 10^{-36}, 4.2 \times 10^{-5}$] $p_1 = 1.7 \times 10^{-1}$ [$4.2 \times 10^{-7}, 2.5 \times 10^{-1}$] $\theta = 6.2 \times 10^{-7}$ [$4.9 \times 10^{-8}, 1.0 \times 10^{-1}$] $k = 6.8 \times 10^4$ [$7.4 \times 10^{-1}, 7.7 \times 10^5$]	The level of susceptibility for a proportion $1 - p_1$ of population follows gamma distribution, and the other proportion p_1 has a level of susceptibility a_1 .

Table S4. Comparison of estimated dose-response models based on model fit to the observed endemic coronavirus challenge data.

	Delta	Gamma	Two-level	Gamma+point-mass
Log-Likelihood	-393.0	-107.2	-98.3	-98.3
No. of parameters	1	2	3	4
AIC*	787.9	218.5	202.6	204.6
Difference in AIC [†]	585.3	15.9	0	2.0

*AIC: Akaike Information Criterion. The lowest value indicates the best model in terms of prediction.

[†]Difference of >10 indicates strong evidence [22]. The values here suggest substantial support for the heterogeneity in susceptibility.